Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready
Woolsey Pharmaceuticals Inc. is managing 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 6 distinct examiners and 5 distinct art units. This distribution shows that each of the pending office actions is being reviewed by a different individual, providing a variety of examiner perspectives. Because there are 5 distinct art units involved, the company must address diverse technical requirements.
KENYON, JOHN S is the busiest examiner, currently responsible for 1 of the 6 pending office actions. The presence of the distinct examiners for the pending actions suggests a lack of examiner-specific concentration in the current prosecution pipeline. Practitioners must be prepared to navigate the individual preferences of the distinct examiners across 5 distinct art units to advance the portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KENYON, JOHN S | 1 | 79.7% | +18.2% |
| WITHERSPOON, SIKARL A | 1 | 86.3% | -20.1% |
| HABTE, KAHSAY | 1 | 84.9% | +7.5% |
| RAMOS LEWIS, JOSMALEN MILAGROS | 1 | 55.1% | +28.3% |
| BAUER, NICOLA MARIA | 1 | 58.7% | +52.1% |
| SCHMITT, MICHAEL J | 1 | 57.0% | +20.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837780 | TASTE-MASKING ORAL FORMULATIONS OF FASUDIL | WITHERSPOON, SIKARL A | — |
| 18712654 | METHODS OF TREATING AGITATION AND OTHER DEMENTIA-ASSOCIATED BEHAVIORAL SYMPTOMS | HABTE, KAHSAY | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18881324 | Oral Liposomal Formulations of Fasudil | KENYON, JOHN S | — |
| 18665262 | METHODS OF TREATING FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS BY ORAL ADMINISTRATION OF FASUDIL | RAMOS LEWIS, JOSMALEN MILAGROS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18005269 | METHODS OF TREATING PROTEINOPATHIES | SCHMITT, MICHAEL J | 154d overdue |
| 18300445 | METHODS OF TREATING CORTICAL DEMENTIA ASSOCIATED WANDERING | BAUER, NICOLA MARIA | 59d overdue |
| 18881324 | Oral Liposomal Formulations of Fasudil | KENYON, JOHN S | — |
| 18665262 | METHODS OF TREATING FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS BY ORAL ADMINISTRATION OF FASUDIL | RAMOS LEWIS, JOSMALEN MILAGROS | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1621 | 2 |
| 1692 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18881324 | Oral Liposomal Formulations of Fasudil | KENYON, JOHN S | 1629 | §102§103§112 | Non-Final OA | — | Pending | Jan 06, 2025 |
| 18837780 | TASTE-MASKING ORAL FORMULATIONS OF FASUDIL | WITHERSPOON, SIKARL A | 1692 | DP | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18712654 | METHODS OF TREATING AGITATION AND OTHER DEMENTIA-ASSOCIATED BEHAVIORAL SYMPTOMS | HABTE, KAHSAY | 1624 | DP | Non-Final OA | — | Pending | May 22, 2024 |
| 18665262 | METHODS OF TREATING FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS BY ORAL ADMINISTRATION OF FASUDIL | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §102§103 | Non-Final OA | — | Pending | May 15, 2024 |
| 18300445 | METHODS OF TREATING CORTICAL DEMENTIA ASSOCIATED WANDERING | BAUER, NICOLA MARIA | 1621 | §103 | Final Rejection | 59d overdue | Pending | Apr 14, 2023 |
| 18005269 | METHODS OF TREATING PROTEINOPATHIES | SCHMITT, MICHAEL J | 1629 | §102§103DP | Final Rejection | 154d overdue | Pending | Jan 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWoolsey Pharmaceuticals Inc. has 6 pending office actions as of October 2026, spread across 4 art units and 6 examiners.
John S Kenyon has the most, with 1 of Woolsey Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
